Advertisement

Cell Death pp 41-59 | Cite as

Molecular Basis of Cell Death Programs in Mature T Cell Homeostasis

  • Carrie L. Lucas
  • Michael J. Lenardo
Chapter

Abstract

Overview of Peripheral T Cell Homeostasis

The lymphocyte is a major class of white blood cell that defends the body from attack by infectious agents and confers long-term protection through immunological memory. Lymphocytes are also involved in pathological immune reactions including graft rejection, allergies, and autoimmune disorders. Their remarkable capacity to proliferate up to 5,000-fold in response to antigen must be counterbalanced by a controlled process of removing cells. This is achieved through molecular pathways of programmed cell death, which maintain selective and specific homeostasis of the numbers of lymphocytes and other immune cells. We focus principally on cell death mechanisms in T lymphocytes that control the number of T cells of a given antigen specificity represented in the finite T cell niche. Here, we discuss the central role of caspases in the regulation of the general pathways of cell-extrinsic and cell-intrinsic T cell apoptosis and programmed necrosis with an overview of their importance for human health.

Keywords

Lymphocyte Death receptor Fas RICD Mitochondria CWID ALPS XLP 

References

  1. 1.
    Lockshin RA, Zakeri Z. Programmed cell death and apoptosis: origins of the theory. Nat Rev Mol Cell Biol. 2001;2:545–50.PubMedGoogle Scholar
  2. 2.
    Check E. Worm cast in starring role for Nobel prize. Nature. 2002;419:548–9.PubMedGoogle Scholar
  3. 3.
    Marx J. Nobel prize in physiology or medicine. Tiny worm takes a star turn. Science. 2002;298(526).Google Scholar
  4. 4.
    Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988;335:440–2.PubMedGoogle Scholar
  5. 5.
    McDonnell TJ, et al. bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell. 1989;57:79–88.PubMedGoogle Scholar
  6. 6.
    Snow AL, Lenardo MJ. Programmed cell death. In: Paul WE, editor. Fundamental immunology. Philadelphia, PA: Lippincott Williams & Wilkins; 2012. pp 718–40.Google Scholar
  7. 7.
    Ellis HM, Horvitz HR. Genetic control of programmed cell death in the nematode C. elegans. Cell. 1986;44:817–29.PubMedGoogle Scholar
  8. 8.
    Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26:239–57.PubMedGoogle Scholar
  9. 9.
    Cohen JJ, Duke RC, Fadok VA, Sellins KS. Apoptosis and programmed cell death in immunity. Annu Rev Immunol. 1992;10:267–93.PubMedGoogle Scholar
  10. 10.
    Lenardo M, et al. Mature T lymphocyte apoptosis–immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol. 1999;17:221–53.PubMedGoogle Scholar
  11. 11.
    Yuan S, et al. Characterization of the extrinsic apoptotic pathway in the basal chordate amphioxus. Sci Signal. 2010;3:ra66.PubMedGoogle Scholar
  12. 12.
    Bajoghli B, et al. Evolution of genetic networks underlying the emergence of thymopoiesis in vertebrates. Cell. 2009;138:186–97.PubMedGoogle Scholar
  13. 13.
    Han J, Zhong CQ, Zhang DW. Programmed necrosis: backup to and competitor with apoptosis in the immune system. Nat Immunol. 2011;12:1143–9.PubMedGoogle Scholar
  14. 14.
    Yu L, et al. Regulation of an ATG7-beclin 1 program of autophagic cell death by caspase-8. Science. 2004;304:1500–2.PubMedGoogle Scholar
  15. 15.
    Freundt EC, et al. The open reading frame 3a protein of severe acute respiratory syndrome-associated coronavirus promotes membrane rearrangement and cell death. J Virol. 2010;84:1097–109.PubMedGoogle Scholar
  16. 16.
    Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol. 2008;9:231–41.PubMedGoogle Scholar
  17. 17.
    Kersse K, Verspurten J, Vanden Berghe T, Vandenabeele P. The death-fold superfamily of homotypic interaction motifs. Trends Biochem Sci. 2011;36:541–52.PubMedGoogle Scholar
  18. 18.
    Lavrik I, et al. The active caspase-8 heterotetramer is formed at the CD95 DISC. Cell Death Differ. 2003;10:144–5.PubMedGoogle Scholar
  19. 19.
    Janssens S, Tinel A. The PIDDosome. DNA-damage-induced apoptosis and beyond. Cell Death Differ. 2012;19:13–20.PubMedGoogle Scholar
  20. 20.
    Luthi AU, Martin SJ. The CASBAH: a searchable database of caspase substrates. Cell Death Differ. 2007;14:641–50.PubMedGoogle Scholar
  21. 21.
    Deveraux QL, et al. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J. 1998;17:2215–23.PubMedGoogle Scholar
  22. 22.
    Deveraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. Nature. 1997;388:300–4.PubMedGoogle Scholar
  23. 23.
    Deveraux QL, et al. Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO J. 1999;18:5242–51.PubMedGoogle Scholar
  24. 24.
    Kaufmann T, Strasser A, Jost PJ. Fas death receptor signalling: roles of Bid and XIAP. Cell Death Differ. 2012;19:42–50.PubMedGoogle Scholar
  25. 25.
    Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell. 2000;102:33–42.PubMedGoogle Scholar
  26. 26.
    Verhagen AM, et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell. 2000;102:43–53.PubMedGoogle Scholar
  27. 27.
    Suzuki Y, et al. A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. Mol Cell. 2001;8:613–21.PubMedGoogle Scholar
  28. 28.
    Chun HJ, et al. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature. 2002;419:395–9.PubMedGoogle Scholar
  29. 29.
    Su H, et al. Requirement for caspase-8 in NF-kappaB activation by antigen receptor. Science. 2005;307:1465–8.PubMedGoogle Scholar
  30. 30.
    Chan FK, et al. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science. 2000;288:2351–4.PubMedGoogle Scholar
  31. 31.
    Schneider P, et al. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med. 1998;187:1205–13.PubMedGoogle Scholar
  32. 32.
    Guicciardi ME, Gores GJ. Life and death by death receptors. FASEB J. 2009;23:1625–37.PubMedGoogle Scholar
  33. 33.
    Migone TS, et al. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity. 2002;16:479–92.PubMedGoogle Scholar
  34. 34.
    Nikolaev A, McLaughlin T, O'Leary DD, Tessier-Lavigne M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature. 2009;457:981–9.PubMedGoogle Scholar
  35. 35.
    Chinnaiyan AM, et al. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science. 1996;274:990–2.PubMedGoogle Scholar
  36. 36.
    Liu J, et al. Enhanced CD4+ T cell proliferation and Th2 cytokine production in DR6-deficient mice. Immunity. 2001;15:23–34.PubMedGoogle Scholar
  37. 37.
    Zhao H, et al. Impaired c-Jun amino terminal kinase activity and T cell differentiation in death receptor 6-deficient mice. J Exp Med. 2001;194:1441–8.PubMedGoogle Scholar
  38. 38.
    Siegel RM, et al. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science. 2000;288:2354–7.PubMedGoogle Scholar
  39. 39.
    Siegel RM, et al. SPOTS: signaling protein oligomeric transduction structures are early mediators of death receptor-induced apoptosis at the plasma membrane. J Cell Biol. 2004;167:735–44.PubMedGoogle Scholar
  40. 40.
    Wang L, et al. The Fas-FADD death domain complex structure reveals the basis of DISC assembly and disease mutations. Nat Struct Mol Biol. 2010;17:1324–9.PubMedGoogle Scholar
  41. 41.
    Krammer PH, Arnold R, Lavrik IN. Life and death in peripheral T cells. Nat Rev Immunol. 2007;7:532–42.PubMedGoogle Scholar
  42. 42.
    Kaufmann T, et al. The BH3-only protein bid is dispensable for DNA damage- and replicative stress-induced apoptosis or cell-cycle arrest. Cell. 2007;129:423–33.PubMedGoogle Scholar
  43. 43.
    McKenzie MD, et al. Proapoptotic BH3-only protein Bid is essential for death receptor-induced apoptosis of pancreatic beta-cells. Diabetes. 2008;57:1284–92.PubMedGoogle Scholar
  44. 44.
    Yin XM, et al. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature. 1999;400:886–91.PubMedGoogle Scholar
  45. 45.
    Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell. 1998;94:491–501.PubMedGoogle Scholar
  46. 46.
    Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell. 1998;94:481–90.PubMedGoogle Scholar
  47. 47.
    Jost PJ, et al. XIAP discriminates between type I and type II FAS-induced apoptosis. Nature. 2009;460:1035–9.PubMedGoogle Scholar
  48. 48.
    Algeciras-Schimnich A, Griffith TS, Lynch DH, Paya CV. Cell cycle-dependent regulation of FLIP levels and susceptibility to Fas-mediated apoptosis. J Immunol. 1999;162:5205–11.PubMedGoogle Scholar
  49. 49.
    Bentele M, et al. Mathematical modeling reveals threshold mechanism in CD95-induced apoptosis. J Cell Biol. 2004;166:839–51.PubMedGoogle Scholar
  50. 50.
    Refaeli Y, Van Parijs L, London CA, Tschopp J, Abbas AK. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity. 1998;8:615–23.PubMedGoogle Scholar
  51. 51.
    Schmitz I, et al. Resistance of short term activated T cells to CD95-mediated apoptosis correlates with de novo protein synthesis of c-FLIPshort. J Immunol. 2004;172:2194–200.PubMedGoogle Scholar
  52. 52.
    Irmler M, et al. Inhibition of death receptor signals by cellular FLIP. Nature. 1997;388:190–5.PubMedGoogle Scholar
  53. 53.
    Ozturk S, Schleich K, Lavrik IN. Cellular FLICE-like inhibitory proteins (c-FLIPs): fine-tuners of life and death decisions. Exp Cell Res. 2012;318:1324–31.PubMedGoogle Scholar
  54. 54.
    Sun H, et al. TIPE2, a negative regulator of innate and adaptive immunity that maintains immune homeostasis. Cell. 2008;133:415–26.PubMedGoogle Scholar
  55. 55.
    Condorelli G, et al. PED/PEA-15: an anti-apoptotic molecule that regulates FAS/TNFR1-induced apoptosis. Oncogene. 1999;18:4409–15.PubMedGoogle Scholar
  56. 56.
    Zheng L, et al. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature. 1995;377:348–51.PubMedGoogle Scholar
  57. 57.
    Hsu H, Shu HB, Pan MG, Goeddel DV. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell. 1996;84:299–308.PubMedGoogle Scholar
  58. 58.
    Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell. 2003;114:181–90.PubMedGoogle Scholar
  59. 59.
    Schneider-Brachert W, et al. Compartmentalization of TNF receptor 1 signaling: internalized TNF receptosomes as death signaling vesicles. Immunity. 2004;21:415–28.PubMedGoogle Scholar
  60. 60.
    Cho YS, et al. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell. 2009;137:1112–23.PubMedGoogle Scholar
  61. 61.
    He S, et al. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell. 2009;137:1100–11.PubMedGoogle Scholar
  62. 62.
    Zhang D, Lin J, Han J. Receptor-interacting protein (RIP) kinase family. Cell Mol Immunol. 2010;7:243–9.PubMedGoogle Scholar
  63. 63.
    Jiang Y, Woronicz JD, Liu W, Goeddel DV. Prevention of constitutive TNF receptor 1 signaling by silencer of death domains. Science. 1999;283:543–6.PubMedGoogle Scholar
  64. 64.
    Peschon JJ, et al. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol. 1998;160:943–52.PubMedGoogle Scholar
  65. 65.
    Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ. 2003;10:45–65.PubMedGoogle Scholar
  66. 66.
    Pan G, et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science. 1997;277:815–8.PubMedGoogle Scholar
  67. 67.
    Clancy L, et al. Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc Natl Acad Sci U S A. 2005;102:18099–104.PubMedGoogle Scholar
  68. 68.
    Gonzalvez F, Ashkenazi A. New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene. 2010;29:4752–65.PubMedGoogle Scholar
  69. 69.
    Wagner KW, et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med. 2007;13:1070–7.PubMedGoogle Scholar
  70. 70.
    Jin Z, et al. Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell. 2009;137:721–35.PubMedGoogle Scholar
  71. 71.
    Finnberg N, Klein-Szanto AJ, El-Deiry WS. TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J Clin Invest. 2008;118:111–23.PubMedGoogle Scholar
  72. 72.
    Janssen EM, et al. CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature. 2005;434:88–93.PubMedGoogle Scholar
  73. 73.
    Lenardo MJ. Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature. 1991;353:858–61.PubMedGoogle Scholar
  74. 74.
    Hornung F, Zheng L, Lenardo MJ. Maintenance of clonotype specificity in CD95/Apo-1/Fas-mediated apoptosis of mature T lymphocytes. J Immunol. 1997;159:3816–22.PubMedGoogle Scholar
  75. 75.
    Takahashi T, et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell. 1994;76:969–76.PubMedGoogle Scholar
  76. 76.
    Snow AL, et al. Critical role for BIM in T cell receptor restimulation-induced death. Biol Direct. 2008;3:34.PubMedGoogle Scholar
  77. 77.
    Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature. 1992;356:314–7.PubMedGoogle Scholar
  78. 78.
    Wong B, Arron J, Choi Y. T cell receptor signals enhance susceptibility to Fas-mediated apoptosis. J Exp Med. 1997;186:1939–44.PubMedGoogle Scholar
  79. 79.
    Boehme SA, Lenardo MJ. Propriocidal apoptosis of mature T lymphocytes occurs at S phase of the cell cycle. Eur J Immunol. 1993;23:1552–60.PubMedGoogle Scholar
  80. 80.
    Garcia-Saez AJ. The secrets of the Bcl-2 family. Cell Death Differ. 2012;19:1733–40.PubMedGoogle Scholar
  81. 81.
    Martinou JC, Youle RJ. Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev Cell. 2011;21:92–101.PubMedGoogle Scholar
  82. 82.
    Boehning D, et al. Cytochrome c binds to inositol (1,4,5) trisphosphate receptors, amplifying calcium-dependent apoptosis. Nat Cell Biol. 2003;5:1051–61.PubMedGoogle Scholar
  83. 83.
    Rong YP, et al. The BH4 domain of Bcl-2 inhibits ER calcium release and apoptosis by binding the regulatory and coupling domain of the IP3 receptor. Proc Natl Acad Sci U S A. 2009;106:14397–402.PubMedGoogle Scholar
  84. 84.
    Wu G, et al. Structural basis of IAP recognition by Smac/DIABLO. Nature. 2000;408:1008–12.PubMedGoogle Scholar
  85. 85.
    Yang QH, Church-Hajduk R, Ren J, Newton ML, Du C. Omi/HtrA2 catalytic cleavage of inhibitor of apoptosis (IAP) irreversibly inactivates IAPs and facilitates caspase activity in apoptosis. Genes Dev. 2003;17:1487–96.PubMedGoogle Scholar
  86. 86.
    Polster BM, Basanez G, Etxebarria A, Hardwick JM, Nicholls DG. Calpain I induces cleavage and release of apoptosis-inducing factor from isolated mitochondria. J Biol Chem. 2005;280:6447–54.PubMedGoogle Scholar
  87. 87.
    Marchetti P, et al. The novel retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphtalene carboxylic acid can trigger apoptosis through a mitochondrial pathway independent of the nucleus. Cancer Res. 1999;59:6257–66.PubMedGoogle Scholar
  88. 88.
    Zou H, Henzel WJ, Liu X, Lutschg A, Wang X. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell. 1997;90:405–13.PubMedGoogle Scholar
  89. 89.
    Yu X, et al. A structure of the human apoptosome at 12.8 A resolution provides insights into this cell death platform. Structure. 2005;13:1725–35.PubMedGoogle Scholar
  90. 90.
    Acehan D, et al. Three-dimensional structure of the apoptosome: implications for assembly, procaspase-9 binding, and activation. Mol Cell. 2002;9:423–32.PubMedGoogle Scholar
  91. 91.
    Reubold TF, Wohlgemuth S, Eschenburg S. Crystal structure of full-length Apaf-1: how the death signal is relayed in the mitochondrial pathway of apoptosis. Structure. 2011;19:1074–83.PubMedGoogle Scholar
  92. 92.
    Reubold TF, Wohlgemuth S, Eschenburg S. A new model for the transition of APAF-1 from inactive monomer to caspase-activating apoptosome. J Biol Chem. 2009;284:32717–24.PubMedGoogle Scholar
  93. 93.
    Pop C, Timmer J, Sperandio S, Salvesen GS. The apoptosome activates caspase-9 by dimerization. Mol Cell. 2006;22:269–75.PubMedGoogle Scholar
  94. 94.
    Razvi ES, Jiang Z, Woda BA, Welsh RM. Lymphocyte apoptosis during the silencing of the immune response to acute viral infections in normal, lpr, and Bcl-2-transgenic mice. Am J Pathol. 1995;147:79–91.PubMedGoogle Scholar
  95. 95.
    Strasser A. The role of BH3-only proteins in the immune system. Nat Rev Immunol. 2005;5:189–200.PubMedGoogle Scholar
  96. 96.
    Hildeman DA, et al. Activated T cell death in vivo mediated by proapoptotic bcl-2 family member bim. Immunity. 2002;16:759–67.PubMedGoogle Scholar
  97. 97.
    Pellegrini M, Belz G, Bouillet P, Strasser A. Shutdown of an acute T cell immune response to viral infection is mediated by the proapoptotic Bcl-2 homology 3-only protein Bim. Proc Natl Acad Sci U S A. 2003;100:14175–80.PubMedGoogle Scholar
  98. 98.
    Ley R, Balmanno K, Hadfield K, Weston C, Cook SJ. Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem. 2003;278:18811–6.PubMedGoogle Scholar
  99. 99.
    Matsui H, Asou H, Inaba T. Cytokines direct the regulation of Bim mRNA stability by heat-shock cognate protein 70. Mol Cell. 2007;25:99–112.PubMedGoogle Scholar
  100. 100.
    Bauer A, et al. The NF-kappaB regulator Bcl-3 and the BH3-only proteins Bim and Puma control the death of activated T cells. Proc Natl Acad Sci U S A. 2006;103:10979–84.PubMedGoogle Scholar
  101. 101.
    Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell. 2006;21:749–60.PubMedGoogle Scholar
  102. 102.
    Oliveira JB, et al. NRAS mutation causes a human autoimmune lymphoproliferative syndrome. Proc Natl Acad Sci U S A. 2007;104:8953–8.PubMedGoogle Scholar
  103. 103.
    Oliveira JB, et al. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood. 2010;116:e35–40.PubMedGoogle Scholar
  104. 104.
    Fisher GH, et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell. 1995;81:935–46.PubMedGoogle Scholar
  105. 105.
    Jackson CE, et al. Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance. Am J Hum Genet. 1999;64:1002–14.PubMedGoogle Scholar
  106. 106.
    Niemela JE, et al. Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis. Blood. 2011;117:2883–6.PubMedGoogle Scholar
  107. 107.
    Takagi M, et al. Autoimmune lymphoproliferative syndrome-like disease with somatic KRAS mutation. Blood. 2011;117:2887–90.PubMedGoogle Scholar
  108. 108.
    Shannon K, Li Q. Oncogenic Ras scales the ALPS. Blood. 2011;117:2747–8.PubMedGoogle Scholar
  109. 109.
    Pachlopnik Schmid J, et al. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency). Blood. 2011;117:1522–9.PubMedGoogle Scholar
  110. 110.
    Proust R, Bertoglio J, Gesbert F. The Adaptor Protein SAP Directly Associates with CD3zeta Chain and Regulates T Cell Receptor Signaling. PLoS One. 2012;7:e43200.PubMedGoogle Scholar
  111. 111.
    Nichols KE, Ma CS, Cannons JL, Schwartzberg PL, Tangye SG. Molecular and cellular pathogenesis of X-linked lymphoproliferative disease. Immunol Rev. 2005;203:180–99.PubMedGoogle Scholar
  112. 112.
    Snow AL, et al. Restimulation-induced apoptosis of T cells is impaired in patients with X-linked lymphoproliferative disease caused by SAP deficiency. J Clin Invest. 2009;119:2976–89.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Laboratory of Immunology, NIAID, NIHBethesdaUSA

Personalised recommendations